{"id":"W2912094423","doi":"10.1200/jco.2019.37.4_suppl.327","title":"Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Nivolumab; Internal medicine; Hepatocellular carcinoma; Sorafenib; Gastroenterology; Cancer; Progressive disease; Clinical endpoint; Clinical trial; Oncology; Immunotherapy; Disease","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001323793,0.0001824363,0.00139741,0.0001562221,0.00003008913,0.000009501267,0.0001214648,0.0003180711,0.0002154288],"category_scores_gemma":[0.0003288926,0.0001243708,0.0002390318,0.0001869269,0.0002044746,0.0001722795,0.00004157699,0.0008867658,0.00001322052],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002598421,"about_ca_system_score_gemma":0.0008399226,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001032068,"about_ca_topic_score_gemma":0.00005187582,"domain_scores_codex":[0.99698,0.0002129064,0.001828089,0.0002614496,0.0003717063,0.0003458503],"domain_scores_gemma":[0.9976007,0.0003606794,0.001248861,0.0002313987,0.0002684421,0.0002898589],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.04032399,0.001135049,0.8887429,0.00005941768,0.0001867424,0.0002309855,0.0001350612,0.000003421326,0.0001417896,0.000007846827,0.0002157883,0.06881702],"study_design_scores_gemma":[0.04856212,0.02517626,0.8932449,0.000275474,0.000102859,0.0001630048,0.000141466,0.00007757273,0.0001155464,0.00002234834,0.03198008,0.0001383803],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9937174,0.001298244,0.000006700967,0.001326781,0.0007496777,0.0004425833,0.00000434596,0.000007233899,0.002447082],"genre_scores_gemma":[0.9962358,0.001059302,0.0008453287,0.001434634,0.0001982991,0.000003008052,0.000005712649,0.00002538845,0.0001925008],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06867864,"threshold_uncertainty_score":0.5071695,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0299375002869407,"score_gpt":0.3545736872949904,"score_spread":0.3246361870080497,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}